InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2024 Milestones and 2025 Clinical Outlook
Kairos Pharma (NYSE American: KAPA) reflected on its 2024 progress and outlined key 2025 milestones in a letter to shareholders. Last year’s achievements included its initial public offering, collaborations with PreCheck Health Services and City of Hope Cancer Center, and advancements in clinical trials for ENV105 targeting prostate and lung cancers. Notable developments also included the first patient dosed in a combination therapy with Osimertinib, expanded…